Ascendis Pharma's IL-2 β/γ Shows Promise in Platinum-Resistant Ovarian Cancer

In the current Phase 1/2 IL-Believe Trial, Ascendis Pharma has released preliminary results indicating clinical efficacy in patients with platinum-resistant ovarian cancer who have had extensive pretreatment and are receiving TransCon IL-2 β/γ in conjunction with chemotherapy. The initial findings will be presented in Poster 762P at the European Society of Medical Oncology's annual conference, ESMO 2024. Four of the initial 18 patients that were part of the data terminated therapy because their condition worsened or they passed away, and 14 of the patients who were deemed efficacious had at least one post-baseline tumour evaluation. Of the patients whose efficacy could be evaluated, 29% (4/14) showed anti-tumor clinical responses, indicating clinical activity in patients who had received a lot of pretreatment.

According to the data, TransCon IL-2 β/γ was generally well-tolerated; tiredness, thrombocytopenia, neutropenia, and anaemia were the most frequent treatment-emergent adverse events associated with combination therapy with TransCon IL-2 β/γ plus chemotherapy. TEAEs connected to TransCon IL-2 β/γ were mostly grade 1 or 2.